Mid-Way Point Reached in Landmark Alzheimers Trial - XanADu
Filed with ASX · · 2 pages · English
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Strong Recruitment Progress in Alzheimers Trial
- New Data Supports Cortisol Hypothesis
- December 2017 Quarterly Report
- Prospectus
- Early Efficacy & Safety Data Planned for XanADu Trial
Later from Actinogen Medical
- March 2018 Quarterly Report
- XanADu Interim Analysis-Continuation Without Change
- $15m Placement Completed-Including US Cornerstone Investor
- Share Purchase Plan
- New Study Sites Added to Accelarate Patient Recruitment
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical